Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2012 Apr 6;261(2):181–188. doi: 10.1016/j.taap.2012.03.024

Figure 5.

Figure 5

Nrf2 silencing increases expression of Cyp1A1, VCAM-1 and MCP-1. Primary endothelial cells were treated with Nrf2 siRNA or control siRNA, and then pretreated with 25–50 µM of EGCG for 3 h, followed by treatment with PCB 126 at 0.25 µM for 16 h. Expression of Cyp1A1 (A), MCP-1 (B), VCAM-1 (C), GST (D) and NQO1 (E) were analyzed in cells. Real-time PCR technique was used to measure expressed mRNA levels. Results represent the mean ± SEM, with n=3. Experiments were repeated a minimum of three times. *Significantly different compared to corresponding DMSO control. #Significantly different between control siRNA and Nrf2 siRNA within the same treatment.

HHS Vulnerability Disclosure